Dec 4 2009
TapeBeat.Com the news and community portal for the serious investor has posted research on GeneLink (GNLK). GeneLink’s approach to well-being utilizes the science of pharmacogenenomics - using individual genetic variations to customize nutritional, skincare products and health maintenance products. GeneLink’s highly credentialed scientific staff has over 500 peer reviewed publications and abstracts, numerous awards, dozens of patents and distinguished careers with some of the world’s foremost public and private biosciences corporations as well as universities. GNLK was ranked number 92 on Technology Fast 500TM, Deloitte LLP’s ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.
Through its Genewize® program, GeneLink incorporates important medical and pharmacogenomic research areas using genetic assessments for early detection of Alzheimer’s and Dementia, Cardiovascular Disease, Metabolic Syndrome and innovative methods for DNA collection. Each (patented or patent pending) GeneLink “panel” is based on a carefully selected set of single nucleotide polymorphisms (SNPs) associated with a particular physiologic condition. GeneLink owns the only patented, FDA reviewed, non-invasive, self-administered DNA collection system available today to collect samples for its nutragenetic and dermagenetic profiling. Since its inception in August 2008, the Genewize® program has created about $10 million in revenue for GNLK.
BMI's influence on disease pathogenesis uncovered in new research